Shanghai, China / San Diego, USA – January 14 2026 — ABM Therapeutics, invested and incubated by Viva BioInnovator (VBI), today announced the transfer of global rights of ABM-168, its proprietary MEK1/2 inhibitor, to Mosaica Medicines, a Boston-based biotechnology company. Under the terms of the agreement, ABM Therapeutics has received an upfront payment and is eligible to receive additional milestone payments tied to the successful development and commercialization of ABM-168.

ABM-168 is a highly potent, allosteric MEK1/2 inhibitor that has demonstrated strong anti-tumor activity both as a monotherapy and in combination with other agents in multiple preclinical animal models. Preclinical studies have also shown that ABM-168 has excellent blood–brain barrier penetration and is capable of effectively targeting brain metastatic cancer cells as well as malignant primary brain tumor cells.

ABM-168 was granted Investigational New Drug (IND) clearance by the U.S. Food and Drug Administration (FDA) in October 2022. A Phase 1 clinical trial (NCT05831995) has been conducted across multiple cancer centers in the United States. In August 2023, ABM-168 also received approval from China's National Medical Products Administration (NMPA) to initiate a Phase 1 clinical trial in patients with advanced solid tumors, with a particular focus on patients with brain metastases or primary brain tumors. The study is designed to evaluate safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity.

About ABM-168
ABM-168 is a novel, highly potent allosteric MEK1/2 inhibitor designed to block oncogenic signaling pathways driven by RAS and RAF mutations or signal amplification, thereby inhibiting cancer cell growth. In vivo studies have demonstrated robust anti-tumor activity when ABM-168 is used alone or in combination with other therapies across a range of models, including glioblastoma orthotopic models, human melanoma intracranial and intracardiac models, colon cancer subcutaneous and orthotopic tumor models, and pancreatic cancer tumor models. ABM-168 has shown effective inhibition of proliferation across multiple cancer cell lines harboring RAS, RAF, and NF1 mutations, along with strong blood–brain barrier penetration.

About ABM Therapeutics
ABM Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapies for the treatment of cancer, with a particular emphasis on blood–brain barrier penetration and brain metastases. ABM’s pipeline includes multiple programs at various stages of discovery and development, many of which are designed to address significant unmet medical needs in cancers affecting the brain.